solid driven growth asset incl even otezla biosimilar repatha neulasta
slightli light inventori build account benefit help drive
upsid off-set weak prolia/xgeva due opex slightli
lower lead high op margin bp given headwind march solid
take impact manag manag re-affirm guidanc
year overal given diversifi product mix outlook favor
navig environ without major impact long-term
like stock ahead pivot readout fall nsclc tezepelumab
asthma omecamtiv heart failur view
tezepelumab succeed therebi unlock new lucr opportun see
stock trade posit data posit tezepelumab
data view risk/reward posit head omecamtiv readout given
low expect see stock trade neg data
rais pt due higher ep driven biosimilar even growth
rais pt base unchang ep vs
previous lower total product rev off-set lower opex relat
slow expenditur ep increas despit slightli lower stock buyback
compani conserv cash environ new total product sale
high end guidanc rais biosimilar
otezla off-set lower prolia xgeva due account lower
given diversifi portfolio impact mute inventori
provid wholesal increas modest amount global
product sale though materi pull prescript size given product mix
includ biolog prescript size increas day relat
typic oral drug
oncolog esrd busi resili otezla benefit clean
safeti profil oral dose prolia weak relat healthcar provid administr
low urgenc osteoporosi
importantli demand biosimilar even remain strong kanjinti mvasi
may margin impact increas dose space inject oncolog drug
even given acut hospit set follow bone fractur seen
pleas see page report import disclosur
like fundament due diversifi product mix biolog franchis
durabl protect product innov pipelin tight control opex
aggress cash return sharehold see near-term risk enbrel sensipar
gener challeng new product launch includ aimovig biosimilar
provid new growth prospect legaci franchis declin opinion amgen
continu provid sustain growth navig turbul water
legaci franchis erod meantim tezepelumab earli stage oncolog pipelin
gain visibl shore confid long-term prospect
data otezla psoriasi mid
data nsclc
data
data tezepelumab asthma
data mm
data
data omecamtiv mecarbil
grow dividend consist stock
neulasta enbrel sensipar eros
less expect
aimovig biosimilar tezepelumab
tezepelumab success becom
revenu growth greater
pipelin contribut substanti
valu model
biosimilar launch exceed
neulasta rapid share loss sensipar
tezepelumab drug
aimovig slow
fail rais dividend pursu
success navig biosimilar competit legaci franchis
still contend patent challeng age brand nevertheless tight opex
control margin expans stock buyback new product launch ep growth
resili manag grow dividend annual major brand includ enbrel
sale neulasta denosumab franchis brand xgeva cancer
prolia osteoporosi sale aranesp/epogen like
tezepelumab asthma solid tumor earli stage oncolog pipelin
solid liquid tumor biosimilar franchis aimovig also provid attract
multipl updat recal enrol pivot
studi nsclc complet quickli re-affirmed today
data would like month follow-up respons
take month get respons usual time analyz data think
data like avail fall
also guid initi data keytruda combo studi nsclc
expect manag note trial paus due
includ trial initi initi impact
get better control manag get readi ramp enrol back
notabl compani confirm nsclc data year
instead present two poster one abstract
bigger cohort origin present esmo one tumor type
start monotherapi vs docetaxel also increment
delay due recal trial initi plan start late march
note decis select docetaxel control arm discuss
regulatori author investig accept singl drug standard care
global manag note enrol patient suffici
power studi show overal surviv benefit
recal histor data show docetaxel modest orr mpf
mo previous treat nsclc importantli tailor trial docetaxel vs erlotinib
egfr tki show kra mutat statu prognost effect docetaxel
therefor high convict confirmatori show posit data
secur full approv nsclc
prior note topic
cowen compani
amgen quarterli model growth us ex-u growth y/i erythropoietin enbrel growth us ex-u sale g-csf growth quarter-over-quart us ex-u us ex-u dmab growth us ex-u kyproli growth us ex-u us ex-u us ex-u us ex-u us ex-u growth probabl product sale growth revenu growth good sold margin margin product incom growth gaap growth share outstand cowen
calcul target price employ one valuat methodolog
includ discount earn analysi discount cash flow analysi net present
valu analysi and/or compar compani analysi analys may may
requir use object measur price-to-earn price-to-sal multipl
well subject measur discount rate
make invest recommend earli stage pre-commerci biotechnolog
compani base upon assess technolog probabl pipelin
success potenti market opportun event success howev
compani lack tradit financi metric believ good
methodolog assign specif target price stock
multipl risk inher invest biotechnolog sector
beyond system risk also clinic regulatori commerci risk addit
biotechnolog compani requir signific amount capit order develop
clinic program capital-rais environ alway chang risk
necessari capit complet develop may readili avail
forecast sale product difficult outlook could alter
competit clinic develop failur reimburs chang new competit
could also impact sale estim pipelin product might fail develop
risk includ clinic develop regulatori price commerci challeng may
prevent financi forecast materi
